Spelling suggestions: "subject:"4he pharmaceutical aindustry"" "subject:"4he pharmaceutical anindustry""
181 |
The impact of competition on the product-market strategies of entities in the pharmaceutical industry / Sharon HorstenHorsten, Sharon January 2004 (has links)
There can be little doubt that competition in the pharmaceutical industry has increased considerably over
the past few years. Growth in the pharmaceutical industry in South Africa has been affected adversely in
recent years by the increased competition from generic drug manufacturers. As soon as a drug comes off
patent, competitors are ready with generic copies, resulting in price drops. Pharmaceutical companies are
therefore forced to continually evaluate their existing strategies, to ensure that their financial performance
remains at the desired level.
This study aims to determine the importance that entities in the pharmaceutical industry attach to
competition during the strategy-formulation process. The study will also attempt to provide an
understanding of how entities have adapted their product-market strategies, as identified by Ansoff, over
the past five years. As an ancillary objective, this research aims to determine whether the level of
competition in the industry has adversely affected the financial performance of the entities competing
within the industry.
Entities within the pharmaceutical industry consider the level of competition in the industry to be very
high, and, accordingly, it is one of the major factors that they consider when determining which product market
strategy to adopt. Because of this, the product-market strategies adopted by entities in the
pharmaceutical industry have changed substantially over the past five years. No strategy is, however,
dominant.
Over the past five years, most of the entities in the pharmaceutical industry have displayed improved
profitability, risk and cash flow-ratios, as well as growth in revenue, net profit and net asset value. This
improvement in financial performance is despite an increased level of competition. It can therefore be
concluded that the level of competition in the pharmaceutical industry is not reflected directly in the
overall financial performance of companies in the industry. / Thesis (M.Com. (Management Accounting))--North-West University, Potchefstroom Campus, 2005.
|
182 |
Essays on markets for technology: the role of licensing as a complementary strategy to internal R&DPalermo, Vincenzo 13 January 2014 (has links)
I study the role of licensed technologies in the R&D development process, the knowledge assimilation mechanism and the patent litigation procedure. I document that the use and adoption of licensed technologies is not a linear process and it has important strategic consequences. First, I focus on the joint effect of external and internal technologies and possible firm-level drivers of this relation. I find that, on average, internal R&D and licensing investments are neither complements nor substitutes. However, firms with higher levels of absorptive capacity, economies of scope, and past licensing experience are able to create positive synergies by combining the two types of investments. In addition, I find that the integration and the adoption of external technology may be limited by internal knowledge accumulation. Firms that experience an inward oriented knowledge accumulation process need to balance the trade-off between internal knowledge reliance and external knowledge assimilation. The negative relation between internal and external knowledge is positively mitigated by two organizational factors: absorptive capacity and the level of decentralization. Finally, assuming that companies are able to adopt external technologies, I find that licensed patents are more reliable than internal ones. In other words, external patents increase the probability of winning a patent lawsuit. Under this circumstance, firms are able to reduce patent uncertainty, limit market entry, and protect future revenue streams.
|
183 |
Effective approaches to minimize the problem of pharmaceuticals and other personal care products in the environment /Pramanick, Papun. January 2007 (has links)
Thesis (M.S.)--Rochester Institute of Technology, 2007. / Typescript. Includes bibliographical references (leaves 66-71).
|
184 |
Innovations, real options, risk and return : evidence from the pharmaceutical and biotechnology industries /Alimov, Azizjon. January 2007 (has links)
Thesis (Ph. D.)--University of Oregon, 2007. / Typescript. Includes vita and abstract. Includes bibliographical references (leaves 109-114). Also available for download via the World Wide Web; free to University of Oregon users.
|
185 |
Equivalence of international conference of harmonization guideline Q1B, option I and II photostability methodsLincoln-Kemp, Melissa January 2008 (has links) (PDF)
Thesis (M.S.)--University of North Carolina Wilmington, 2008. / Title from PDF title page (October 20, 2008) Includes bibliographical references (p. 58-60)
|
186 |
Implications of the WTO-trips agreement from a national innovation systems perspective : the pharmaceutical industry in Egypt /Abdelgafar, Basma Ibrahim, January 1900 (has links)
Thesis (Ph. D.)--Carleton University, 2003. / Includes bibliographical references (p. 302-317). Also available in electronic format on the Internet.
|
187 |
The influence of experience on organizational search, knowledge creation, and performanceMannor, Michael, J. January 2008 (has links)
Thesis (Ph.D.)--Michigan State University. Dept. of Management, 2008. / Title from PDF t.p. (viewed on July 20, 2009) Includes bibliographical references (p. 130-145). Also issued in print.
|
188 |
Patents, pills, poverty and pandemic : the ethical issues /Brown, Walter. January 2003 (has links)
Thesis (M.A. (Philosophy)) - Rhodes University, 2003. / A thesis in partial fulfilment of the requirements for the degree of Master of Arts.
|
189 |
Modelling stock market performance of firms as a function of the quality and quantity of intellectual property ownedChauhan, Lokendra P. S. January 2007 (has links)
Thesis (M. S.)--Public Policy, Georgia Institute of Technology, 2008. / Hicks, Diana, Committee Chair ; Rouse, Bill, Committee Co-Chair ; Bodner, Douglas, Committee Member.
|
190 |
Δομική ανάλυση της φαρμακευτικής αγοράς στην ΕλλάδαΠαπαγεωργίου, Πολυξένη 21 October 2011 (has links)
Ο σκοπός της παρούσης εργασίας είναι η ανάλυση της φαρμακευτικής βιομηχανίας (λόγω της πολυπλοκότητας του χώρου) με βάση το μοντέλο του Porter (το πιο κοινώς αποδεκτό μοντέλο για την ανάλυση μιας βιομηχανίας), μοντέλο 5 δυνάμεων που ορίζουν τον ανταγωνισμό στη βιομηχανία.
Ο κλάδος της φαρμακευτικής βιομηχανίας είναι ένας από τους σημαντικότερους υποκλάδους της χημικής βιομηχανίας, και αποτελεί ένα ζωτικό και υποστηρικτικό παράγοντα της απασχόλησης και της ανάπτυξης της Εθνικής Οικονομίας, ειδικά για μια χώρα σαν την Ελλάδα που δε διαθέτει βαριά βιομηχανία. Επιπλέον η Ελληνική φαρμακευτική βιομηχανία λειτουργεί σ’ ένα πολυσύνθετο και ασταθές περιβάλλον, το οποίο δέχεται πολλές πιέσεις από την ίδια την αγορά και διάφορους παράγοντες που τη διέπουν. Δεδομένης λοιπόν της σημαντικότητας αυτού του κλάδου για τη χώρα μας, και τις ραγδαίες αλλαγές που τον χαρακτηρίζουν την τελευταία περίοδο, η φαρμακευτική βιομηχανία θ’ αποτελέσει αντικείμενο μελέτης της συγκεκριμένης εργασίας.
Σύμφωνα με το Michael Porter, μια αυθεντία στη στρατηγική ανταγωνισμού, η επιτυχία μιας επιχείρησης, η οποία είναι η συνεχής αύξηση της κερδοφορίας, καθορίζεται από 5 βασικές δυνάμεις ανταγωνισμού: απειλή νέων εισόδων, ανταγωνισμός μεταξύ των υπαρχόντων επιχειρήσεων, απειλή των υποκατάστατων προïόντων ή υπηρεσιών, διαπραγματευτική δύναμη αγοραστών, και διαπραγματευτική δύναμη προμηθευτών. Με βάση τις 5 δυνάμεις ανταγωνισμού κατά Porter, που διέπουν τον κλάδο της φαρμακευτικής βιομηχανίας θα γίνει μια προσπάθεια να εξεταστούν οι αλλαγές που καθορίζονται από αυτές, και να γίνει μια πρώτη προσέγγιση σχετικά με το μέλλον της βιομηχανίας στην Ελλάδα και τις τάσεις της αγοράς. Πιο συγκεκριμένα ο σκοπός είναι η εξέταση της φαρμακευτικής αγοράς από όσο πιο πολλά σημεία αναφοράς γίνεται και μ’ αυτή τη λογική ως προμηθευτές (Suppliers) θεωρούνται οι φαρμακευτικές εταιρείες και ως αγοραστές (Buyers) όλες οι οντότητες επιλογής, πληρωμής και κατανάλωσης των προïόντων.
Να σημειωθεί ότι τέτοιου είδους ανάλυση δεν έχει πραγματοποιηθεί για την ελληνική πραγματικότητα, κάτι που αποτέλεσε ένα ακόμη κίνητρο για την πραγματοποίηση αυτής της εργασίας. / -
|
Page generated in 0.1138 seconds